Now showing items 1-1 of 1
Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: Translational implications
(NRC Research Press, 2018-11)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to prevent heart failure and reduce cardiovascular death in patients with type 2 diabetes (T2DM) and cardiovascular disease (CVD). Whether or not SGLT2 ...